Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04743245 · ClinicalTrials.gov registry record · NA

Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.

A NA study of Acute Myocardial Infarction and STEMI, sponsored by TherOx.

Recruiting
Registry status
NA
Development phase
434
Enrollment target
1
Study location

NCT04743245 is a NA study of Acute Myocardial Infarction and STEMI that is actively recruiting participants, run by TherOx. The registered enrollment target is 434 participants, below the 1,859-participant average among 19 other Acute Myocardial Infarction trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04743245, a NA study of Acute Myocardial Infarction and STEMI, is actively recruiting participants, sponsored by TherOx.

RECRUITING
Registry status
NA
Development phase
434 participants
Enrollment target
1
Study location

Study Summary

A multi-center randomized post-approval evaluation of delivery of intracoronary hyperoxemic supersaturated Oxygen therapy for 60 minutes in anterior AMI patients with successful reperfusion (via PCI) within 6 hours after onset of symptoms compared to standard therapy

Interventions

  • DEVICE TherOx DownStream System
  • DEVICE PCI

Study Locations (1)

Massachusetts

  • Baystate Medical Center - Springfield

Trial Details

FieldValue
Enrollment Target 434 participants
Start Date 2022-08-02
Est. Completion 2026-04-30
Phase NA

Sponsor

TherOx

6 total trials

What the Registry Record Tells You About NCT04743245

The ClinicalTrials.gov registry entry for NCT04743245 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 434 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,859-participant average among 19 other Acute Myocardial Infarction trials with a reported enrollment target (77% lower). The listed sponsor is TherOx, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Myocardial Infarction appearing as the primary indexed condition, and to 2 interventions - of which TherOx DownStream System is the first listed.

NCT04743245 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04743245 about?

NCT04743245 is a clinical study titled "Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.". A multi-center randomized post-approval evaluation of delivery of intracoronary hyperoxemic supersaturated Oxygen therapy for 60 minutes in anterior AMI patients with successful reperfusion (via PCI) within 6 hours after onset of symptoms compared to standard therapy

What is the current status of trial NCT04743245?

This trial is currently recruiting. It is a NA study. The enrollment target is 434 participants. The study started on 2022-08-02. Estimated completion is 2026-04-30.

What conditions does trial NCT04743245 study?

This clinical trial studies the following conditions: Acute Myocardial Infarction, STEMI.

What interventions are being tested in trial NCT04743245?

The interventions under investigation include: TherOx DownStream System (DEVICE), PCI (DEVICE).

Who is sponsoring clinical trial NCT04743245?

This trial is sponsored by TherOx, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04743245 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Myocardial Infarction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.